Medicover Genetics announces compliance of TarCET Kit with the In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746

Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

Medicover Genetics, a leader in genetic testing and diagnostics, is proud to announce that TarCET Kit, NGS-based kit assays and their accompanied accessories UltraVerse Index Oligos, have been officially CE marked under In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746. This compliance with the IVDR signifies that our products adhere to rigorous regulatory standards, ensuring both efficacy and patient safety across the European market.

Medicover Genetics’ TarCET Kit provides a comprehensive suite of panels, covering a wide range of genetic conditions, including carrier screening, metabolic disorders, cardiovascular diseases, hereditary cancers, infertility, and neonatal screening. TarCET Kit cannot be used directly to identify a genetic condition, but only in combination with an IVD Analysis Software.

“Securing IVDR compliance for the TarCET Kit Panels is a significant milestone for Medicover Genetics,” said Dr. Stefan Mehrle, Head of Business Unit Medicover Genetics. “This accomplishment underscores our commitment to advancing genetic science while ensuring the highest standards of safety and quality. By providing reliable tools, we empower healthcare professionals to make better-informed decisions that improve patient outcomes.”

TarCET Kit Intended Use: TarCET Kit is a reagent kit including library preparation and targeted capture enrichment. The kit is intended for use with genomic DNA from human cells for library preparation and capture enrichment for Next Generation Sequencing (NGS) applications. The kit can be used to target specific regions of the genome with validated DNA hybridization probe panels supplied in the kit. All further downstream analyses can be performed in conjunction with the IVD VEGA analysis software, not provided in this kit, or using an independent IVD analysis software.

For further information, please contact: Irina Cluve, Strategic Marketing and Communications Director, Diagnostic Services, Medicover,

Last updated: June 8, 2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases

  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA- and ISO15189 accredited, GMP- and ISO9001 and 13485 certified

Are you a patient?

Are you a physician?